| Host: |
HEK293 cells |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human TIGIT-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications. |
| Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Human TIGIT at 1.5 Mu g/mL (100 Mu L/well) can bind Human CD155 with a linear range of 0.15-1.2 Mu g/mL. |
| Gene Symbol: |
TIGIT |
| Gene ID: |
201633 |
| Uniprot ID: |
TIGIT_HUMAN |
| Immunogen Region: |
Met22-Pro141 |
| Immunogen: |
Recombinant Human TIGIT Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Met22-Pro141) of human TIGIT (Accession #NP_776160.2) fused with a 6×His tag at the C-terminus. |
| Tissue Specificity | Expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). |
| Function | Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. |
| Protein Name | T-Cell Immunoreceptor With Ig And Itim DomainsV-Set And Immunoglobulin Domain-Containing Protein 9V-Set And Transmembrane Domain-Containing Protein 3 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane Protein |
| Alternative Protein Names | T-Cell Immunoreceptor With Ig And Itim Domains proteinV-Set And Immunoglobulin Domain-Containing Protein 9 proteinV-Set And Transmembrane Domain-Containing Protein 3 proteinTIGIT proteinVSIG9 proteinVSTM3 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
